Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launchPresented interim results from ongoing...
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics